Inhaled AR-501 in Healthy Adults and CF Patients with P. aeruginosa

Phase 2, randomised, double-blind trial of gallium citrate in cystic fibrosis (CF) and Pseudomonas aeruginosa infection, sponsored by Aridis Pharmaceuticals, Inc. Primary endpoints: Clinical safety profile (adverse events) - Single Ascending Dose at 28 days and Clinical safety profile (adverse events) - Multiple Ascending Dose at 28 days. Status: unknown.